JERUSALEM--(BUSINESS WIRE)--Jan. 15, 2015--
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) announced today that it
will release its fourth quarter 2014 financial results on Thursday,
February 5, 2015 at 7:00 a.m. ET.
Teva will host a conference call and live webcast on the same day, at
8:00 a.m. ET to discuss its fourth quarter 2014 results and overall
business environment. A Question & Answer session will follow this
discussion.
In order to participate, please dial the following numbers (at least 10
minutes before the scheduled start time): United States 1-866-434-1115;
Canada 1-866-992-3607 International +44(0) 1452 589509; passcode:
66308620. For a list of other international toll-free numbers, click here.
A live webcast of the call will also be available on Teva's website at: www.tevapharm.com.
Please log in at least 10 minutes prior to the conference call in order
to download the applicable audio software.
Following the conclusion of the call, a replay of the webcast will be
available within 24 hours on the Company's website. The replay can also
be accessed until March 12, 2015, 10:00 a.m. ET by calling United States
1-866-247-4222; Canada 1-866-878-9237 or International +44(0) 1452
550000; passcode: 66308620.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic
drugs as well as innovative and specialty pharmaceuticals and active
pharmaceutical ingredients. Headquartered in Israel, Teva is the world's
leading generic drug maker, with a global product portfolio of more than
1,000 molecules and a direct presence in approximately 60 countries.
Teva's Specialty Medicines businesses focus on CNS, respiratory,
oncology, pain, and women's health therapeutic areas as well as
biologics. Teva currently employs approximately 45,000 people around the
world and reached $20.3 billion in net revenues in 2013.
Source: Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd.
IR Contacts:
Kevin C.
Mannix, United States, 215-591-8912
or
Ran Meir, United
States, 215-591-3033
or
Tomer Amitai, Israel, 972 (3)
926-7656
or
PR Contacts:
Iris Beck Codner, Israel,
972 (3) 926-7246
or
Denise Bradley, United States,
215-591-8974